Dr. Pavlovic-Ganascia manages coordination of French and European activities related to the Health Technology Assessment (HTA), notably early dialogue of HTA bodies on health technology development and methodology guidelines. She has served as EunetHTA Co-Lead for methodology guidelines on the relative effectiveness assessment of pharmaceuticals, and Lead for collaborative actions on improving initial and additional evidence generation for HTA.

Previously Dr. Pavlovic-Ganascia was Head of Scientific Advice Unit at the French Medicines Agency, Vice-Chair of Scientific Advice Working Party and a member of both the Efficacy Working Party and Biosimilar Medicinal Products Working Party at the European Medicines Agency (EMA). At EMA she was responsible for pre-marketing authorization domain with methodology input on product development and assessment. Dr. Pavlovic-Ganascia is a practicing dermatologist in Tenon University Hospital in Paris. She has published 30 articles and abstracts in peer-reviewed journals in the fields of dermatology and regulatory science.

The PRO & eCOA Congress agenda is designed for professionals in clinical operations, data management, regulatory affairs, outsourcing, eClinical technologies, and health outcomes. Attendees gain expertise in the science, technologies and regulatory requirements of clinical outcomes assessments. Topics include:

• Best practices, implementation strategies, and operational insights
• Innovative ways sponsors use ePRO
• New trends in patient-based eClinical integrations and technologies
• Regulatory updates on what’s expected from PRO and eCOA data

Register for the PRO & eCOA Congress Europe

PHT invites all Congress alumni to join the PRO & eCOA Congress LinkedIn Community to exchange information, ideas and experiences throughout the year.